Key result
Adjunct low-molecular-weight heparin significantly improved the live birth rate in women with ≥3 recurrent implantation failures compared with control (RR 1.79; 95% CI 1.10-2.90; P=0.02).
Why the study?
Does adjunct low-molecular-weight heparin improve live birth rates in women with recurrent implantation failure undergoing IVF?
Population
Women with recurrent implantation failure undergoing IVF.
Comparison
Low-molecular-weight heparin adjunct therapy vs Control or placebo
Design
Meta-analysis
Authors
Loading...
LMWH may raise LBR in ≥3 RIF; leaves open confirmation in larger RCTs before routine use.
Meta-Analysis (n=245)
Does adjunct low-molecular-weight heparin improve live birth rates in women with recurrent implantation failure undergoing IVF?
Relative Risk: 1.79 (95% CI 1.1–2.9)
Number Needed to Treat: 8
p-value: p=0.02
Adjunct LMWH may improve live birth rates in women with ≥3 recurrent implantation failures undergoing IVF, though evidence is limited by small sample sizes.
Potdar et al. (2013) conducted a meta-analysis in Recurrent implantation failure (RIF) (n=245). Low-molecular-weight heparin (LMWH) vs. Control/placebo was evaluated on Live birth rate per woman (RR 1.79, 95% CI 1.10-2.90, p=0.02). Adjunct low-molecular-weight heparin significantly improved the live birth rate in women with ≥3 recurrent implantation failures compared with control (RR 1.79; 95% CI 1.10-2.90; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: